Status:
RECRUITING
Dexamethasone for Cerebral Toxoplasmosis
Lead Sponsor:
Universitas Padjadjaran
Conditions:
Toxoplasmosis, Cerebral
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with prop...
Detailed Description
Steroid produces a raising expression of anti inflammation genes (NF-κB, IκB-α and antagonist receptor IL-1) and inhibits pro inflammation cytokines ( TNF-α and IL-1β). It also works as anti edema by ...
Eligibility Criteria
Inclusion
- Age 18 years or above.
- Clinical signs and symptoms compatible to cerebral toxoplasmosis
- Serology HIV positive
- Immunoglobulin G anti-toxoplasma titre is positive
- One or more mass lesions on the neuroradiological finding
- None or less than 3 days of dexamethasone therapy taken
- Written informed consent from the patients or from close relatives of the patient if the patient is unconscious.
Exclusion
- History of anti-toxoplasmosis administrattion for more than 5 days before recruitment
- Hypersensitivity or other contraindication to dexamethasone
- Pregnancy
Key Trial Info
Start Date :
April 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT04341155
Start Date
April 16 2021
End Date
July 1 2025
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hasan Sadikin General Hospital
Bandung, West Java, Indonesia, 40161